My take...IMO in order to show significant SP appreciation, on the Cdn markets you need the following factors in place:
- a great story/ demonstrate that you are meetiing a significant and as yet unmet market need
- preferably demonstrated and actual revenue growth
- a favourable overall market environment
- liquidity
- expert IR and promotion.
IMO in order to show SP appreciation on the US markets you need the following factors:
- a great story/ demonstrate that you are meetiing a significant and as yet unmet market need
- If medical, ideally an FDA approval or anticipation of an eventual FDA approval (eg. Phase 1 thru 3 Trials). Note: less dependence on actual revenues.
- Ideally, for max appreciation, a favourable Biotech market (2020 Yes we were there, 2021, and 2022 so far, not so much)
- a favourble overall market environment.
The above are generalities only - there are excpetions.
Comments:
We are not active in the US market (yet)
Regarding Canada. only the # 1 point is covered (so far), although I agree FF, it could be simplified and elucidated upon.
# 2 seems to be on its way/ in the works (anxiously awaiting Q2 and Q3)
# 3 is a bit of a ST problem
#4 and # 5 need to be worked on by Mgt. tout de suite
To get to "next level" appreciation, you have to figure out a pathway to the US market, again IMO.
Patience will be required here. Only the patient will be rewarded (...oh and Yes the lung transplant patients & candidates will be greatly rewarded as well)..
MM